NewAmsterdam Pharma Company N.V. Files Form 8-K: Key Takeaways for Investors

NewAmsterdam Pharma Company N.V. (“the Company”) has filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) dated April 20, 2026. Below, we break down the important details, potential share price sensitivities, and what shareholders should know from this filing.

Key Highlights from the Filing

• Filing Type: Form 8-K – Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
• Date of Report: April 20, 2026
• Company Name: NewAmsterdam Pharma Company N.V.
• SEC File Number: 001-41562
• Trading Symbols:
  • Ordinary Shares: NAMS (NASDAQ)
  • Warrants: NAMSW (NASDAQ)
• Registered Securities:
  • Ordinary shares, nominal value €0.12 per share
  • Warrants to purchase ordinary shares
• Business Address: Gooimeer 2-35, 1411 DC, Naarden, Netherlands. Phone: +31 (0)35 206 2971
• Former Name: NewAmsterdam Pharma Co B.V. (name changed on July 1, 2022)

Key Sections Relevant to Investors

• Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers:
  The filing includes an Item 5.02 heading, which is typically used to disclose significant events such as the departure or appointment of directors or key officers, or changes in compensation arrangements. However, the actual details and substance under this item are not present in the filing. There is no description of any departures, appointments, or compensatory changes reported in this Form 8-K.

Other Compliance and Administrative Details

• No Written or Soliciting Communications: The company has indicated that this 8-K is not being filed to satisfy any written communications or soliciting materials under SEC rules.
• No Pre-Commencement Communications: The company has indicated that this filing does not relate to pre-commencement tender or issuer tender offers.
• Not an Emerging Growth Company: The company does not qualify as an emerging growth company under SEC definitions at this time.

Potential Price Sensitivity and Shareholder Impact

Despite the Form 8-K referencing Item 5.02 (typically a section for material leadership or compensation events), the filing does not disclose any actual events, changes, or material developments related to management, the board, or executive compensation. There are also no disclosures of mergers, acquisitions, business updates, or significant contractual developments.

The only substantive information is administrative in nature, such as company details, trading symbols, and the fact that the company is not invoking any of the special communication or tender offer rules.

Conclusion: Is There Any Newsworthy or Price-Sensitive Disclosure?

NIL – There are no new material events, management changes, or disclosures in this Form 8-K that would be expected to impact the share price or inform investment decisions. Shareholders and investors do not need to take any action based on this filing.

Disclaimer: This article is a summary interpretation of a regulatory filing and is provided for informational purposes only. It does not constitute investment advice or a recommendation to buy, sell, or hold any securities. Investors should review official SEC filings and consult with a qualified financial advisor before making investment decisions.

View NewAmsterdam Pharma Co N.V. Historical chart here